Evidence map›Paper›PMID 37376671›Full record

ReviewViruses2023

Thinking beyond Vaccination: Promising Add-On Strategies to Active Immunization and Vaccination in Pandemics-A Mini-Review.

Franz Tatzber, Willibald Wonisch, Ulrike Resch, Wolfgang Strohmaier, Meinrad Lindschinger, Sabrina Mörkl, Gerhard Cvirn

Open access · goldAbstract readReview
In one paragraph

Review in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Franz TatzberOmnignostica Ltd., 3421 Höflein an der Danube, Austria.
Willibald WonischOmnignostica Ltd., 3421 Höflein an der Danube, Austria.ORCID 0000-0001-7171-9539
Ulrike ReschDepartment of Vascular Biology and Thrombosis Research, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-8380-9555
Wolfgang StrohmaierDr. Strohmaier & Partner Ltd., 1050 Vienna, Austria.
Meinrad LindschingerOutpatient Clinic Laßnitzhöhe, Institute of Nutritional and Metabolic Diseases, 8301 Laßnitzhöhe, Austria.
Sabrina MörklDivision of Medical Psychology, Psychosomatics and Psychotherapeutic Medicine, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0001-5034-6358
Gerhard CvirnOtto Loewi Research Center, Division of Physiological Chemistry, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0002-1410-1844
Medical University of Graz · ATMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is little doubt that final victories over pandemics, such as COVID-19, are attributed to herd immunity, either through post-disease convalescence or active immunization of a high percentage of the world's population with vaccines, which demonstrate protection from infection and transmission and are available in large quantities at reasonable prices. However, it is assumable that humans with immune defects or immune suppression, e.g., as a consequence of allograft transplantation, cannot be immunized actively nor produce sufficient immune responses to prevent SARS-CoV-2 infections. These subjects desperately need other strategies, such as sophisticated protection measures and passive immunization. Hypertonic salt solutions attack vulnerable core areas of viruses; i.e., salt denatures surface proteins and thus prohibits virus penetration of somatic cells. It has to be ensured that somatic proteins are not affected by denaturation regarding this unspecific virus protection. Impregnating filtering facepieces with hypertonic salt solutions is a straightforward way to inactivate viruses and other potential pathogens. As a result of the contact of salt crystals on the filtering facepiece, these pathogens become denatured and inactivated almost quantitatively. Such a strategy could be easily applied to fight against the COVID-19 pandemic and other ones that may occur in the future. Another possible tool to fight the COVID-19 pandemic is passive immunization with antibodies against SARS-CoV-2, preferably from human origin. Such antibodies can be harvested from human patients' sera who have successfully survived their SARS-CoV-2 infection. The disadvantage of a rapid decrease in the immunoglobulin titer after the infection ends can be overcome by immortalizing antibody-producing B cells via fusion with, e.g., mouse myeloma cells. The resulting monoclonal antibodies are then of human origin and available in, at least theoretically, unlimited amounts. Finally, dry blood spots are a valuable tool for surveilling a population's immunity. The add-on strategies were selected as examples for immediate, medium and long-term assistance and therefore did not raise any claim to completeness.

Indexed as

COVID-19AnimalsAntibodies, NeutralizingAntibodies, ViralHumansMicePandemicsSARS-CoV-2VaccinationAntibodies, NeutralizingAntibodies, Viraldry blood spotfiltering face piecehuman monoclonal antibodyhypertonic salt solutionimpregnation

Identifiers

PMID37376671
PMCPMC10304478
OpenAlexW4380997092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.